On the third day of JPM 2024, FENIX has provided coverage of presentations by other CVRM companies, including Terns, Esperion, Ionis, Amarin, Embecta, and Viatris. Tomorrow is the final day of the JPM 2024 conference with presentations from Lexicon, Mannkind, and Xeris.
Three cardiometabolic-related news items have been observed: Senseonics announced a series of business updates regarding the company’s implantable CGM sensors (view press release); Esperion and Daiichi Sankyo announced a $125M amendment to their collaboration, which includes a resolution to their commercial dispute (view press release); and Better Therapeutics and Glooko announced a partnership to integrate BT’s AspyreRx digital behavior treatment for T2DM into Glooko’s diabetes management platform (view press release). Below, FENIX provides highlights and insights for the respective news items.
Four cardiometabolic-related news items have been observed from Novo/Alkermes, Fractyl, AZ, and Esperion. Below, FENIX provides highlights and insights into the respective news items.
A series of CVRM-related news items have been observed at AHA 2023 from Roche/Alnylam, Amgen, Amarin, Esperion, Lexicon, and Cleerly. Below, FENIX provides highlights and insights into the respective news items.
A series of cardiometabolic-related news items have been observed from OrsoBio, Diamyd, Esperion, Altimmune, MannKind, and Viatris. Below, FENIX provides highlights and insights into the respective news items.
Four cardiometabolic-related news items have been observed: Novartis announced long-term Leqvio (inclisiran) data from ORION-8 were presented at the ESC 2023 conference (view press release); Insulet initiated the full market release of the Omnipod 5 AID system in Germany (view press release); Esperion presented additional bempedoic acid (BA) results from the CLEAR Outcomes study at ESC 2023 (view press release); and Amgen presented results from the off-treatment extension of the Ph2 olpasiran OCEAN(a)-DOSE study (view press release). Below, FENIX provides highlights and insights for the respective news items.
Four cardiometabolic-related news items have been observed: Altimmune announced enrollment of the first subject in its Ph2b IMPACT trial evaluating the efficacy and safety of pemvidutide (QW GLP-1/GCG dual agonist) in NASH (view press release); and Pfizer (press release; slides), Esperion (press release; slides), and Merck (press release; slides) hosted their respective Q2 ‘23 earnings calls. Below, FENIX provides highlights and insights into the respective news items.
A series of cardiometabolic news items have been observed from NICE, Insulet, Esperion, Nemaura, NeuroBo, and Terns. Below, FENIX provides highlights and insights for the respective news items.
On the second day of ADA 2023, ten cardiometabolic-related news items were observed from Lilly, Zealand, BI, Novo Nordisk, Biomea Fusion, Sciwind Biosciences, Medtronic, Vertex, and Esperion. Below, FENIX provides context and analysis for the announcements.
A series of cardiometabolic-related news items have been observed from FDA, Esperion, Glyscend, and Pharming/Novartis. Below, FENIX provides highlights and insights into the respective news items.